ICON Completes the Acquisition of Clinical Research Management, Inc.
19 Setembro 2016 - 7:00AM
Business Wire
Acquisition extends ICON’s presence in the
market for government sponsored research and enhances capabilities
in Vaccines and Infectious Disease
ICON plc, (NASDAQ:ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has completed the previously announced acquisition of Clinical
Research Management, Inc. (ClinicalRM).
ClinicalRM provides full service and functional research
solutions to a broad range of U.S. government agencies. Their
extensive expertise extends across basic and applied research,
infectious diseases, vaccine development and testing and response
to bio-threats. In addition, they have worked in collaboration with
government and commercial customers to respond to the threat of
global viral epidemics.
Commenting on the acquisition, ICON’s Chief Executive Officer,
Ciaran Murray said: “ClinicalRM has a strong track record of
partnering successfully with government agencies and NGOs. They
will provide a platform for ICON to further penetrate this
significant market segment as we continue to grow and diversify our
customer base. ClinicalRM’s work in the area of global vaccine
development will further enhance our capabilities in this important
area to the benefit of customers and patients globally.”
About ClinicalRM
ClinicalRM is a full-service Contract Research Organization
specializing in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. The organization helps customers get their products to
market faster with a wide array of research, regulatory and sponsor
services within the U.S. and around the globe. From international
partnerships and affiliations to government relations and local
alliances, ClinicalRM delivers a synergy in the global market with
projects spanning the government, academic and commercial
marketplaces. ClinicalRM has a distinct ability to provide
boots-on-the-ground and rapid response efforts to global health
crises. More information is at http://www.clinicalrm.com/
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. ICON specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently
operates from 89 locations in 37 countries and has approximately
12,300 employees.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005486/en/
ICON Media ContactNiamh
MurphyICON+35312912180niamh.murphy@iconplc.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024